propafenone has been researched along with Atrioventricular Nodal Re-Entrant Tachycardia in 43 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 6.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 5.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "Spontaneous monomorphic and polymorphic ventricular tachycardias (VT) were observed during monitoring." | 5.33 | Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report. ( Dinckal, MH; Karaca, M, 2006) |
| "Propafenone is an antiarrhythmic drug used in the treatment of life-threatening ventricular tachyarrhythmias." | 5.30 | Propafenone-induced drug fever in the absence of agranulocytosis. ( Gerling, BR; Greenberg, ML; Holzberger, PT; O'Rourke, DJ; Palac, RT, 1997) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 5.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| " In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, randomized trial, was initiated to compare metoprolol, amiodarone, propafenone, and ICD implantation in patients surviving sudden cardiac death due to documented ventricular tachycardia and/or ventricular fibrillation." | 5.07 | Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators. ( Cappato, R; Kuck, KH; Rüppel, R; Schneider, MA; Siebels, J, 1993) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "Ventricular arrhythmia (VA) can occur during propafenone therapy in atrial fibrillation (AF) patients with structurally normal heart." | 3.81 | Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. ( Chang, SL; Chang, Y; Chao, TF; Chen, SA; Chen, YY; Chien, KL; Chiou, CW; Chong, E; Chung, FP; Hu, YF; Liao, JN; Lin, CY; Lin, YJ; Lo, LW; Tuan, TC, 2015) |
| "The electrophysiological effects of combination therapy of mexiletine and propafenone were assessed using standard 12-lead electrocardiogram (standard ECG), signal-averaged ECG (SAECG), and ambulatory ECG in 31 patients with ventricular arrhythmias." | 3.68 | Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy. ( Haruna, M; Kato, H; Lee, S; Machii, T; Nonokawa, M; Takanaka, C; Yabe, S, 1992) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| " After a period of placebo administration, all patients underwent three consecutive periods during which they received Pr IR at the dosage of 150 mg x 3, Pr SR at the dosage of 225 mg x 2, Pr SR at the dosage of 325 mg x 2." | 2.69 | [Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms]. ( Massari, F; Mastropasqua, F; Pitzalis, MV; Rizzon, P; Totaro, P, 1998) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 2.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| " The dosage from 50 to 100 mg/day made no difference." | 2.68 | Preliminary study of the effects of metoprolol and propafenone on ventricular arrhythmia with positive ventricular late potential. ( Duan, Y; Gao, E; Li, H; Yang, C; Zhou, Y, 1997) |
| "Overall efficacy of ventricular tachycardia pace termination was 69% and the time required to stop ventricular tachycardia was 14." | 2.67 | Randomized cross-over evaluation of two adaptive pacing algorithms for the termination of ventricular tachycardia. ( Green, MS; Kantoch, MJ; Tang, AS, 1993) |
| "In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, multicenter, randomized controlled study, was started in survivors of sudden cardiac death resulting from documented ventricular tachyarrhythmias." | 2.67 | Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). ( Kuck, KH; Siebels, J, 1994) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| "Procainamide is effective for stable ventricular tachycardia, and amiodarone is effective in the treatment of shock-refractory ventricular fibrillation." | 2.41 | Intravenous antiarrhythmic agents. ( Dorian, P; Pinter, A, 2001) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 1.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "Propafenone is a class 1C antiarrhythmic drug used in the second-line management of supraventricular and ventricular arrhythmias and, when unintentionally ingested, can lead to severe and life-threatening poisoning." | 1.51 | Ventricular Tachycardia Induced by Propafenone Intoxication in a Pediatric Patient. ( Di Mita, O; DʼAnna, C; Marzuillo, P; Pappacoda, S; Ponticiello, E; Rosa, M; Tipo, V, 2019) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially lethal inherited arrhythmia syndrome induced by adrenergic stress." | 1.48 | A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. ( Duan, H; Hua, Y; Li, Y; Lu, Y; Qiao, L; Wang, C; Yan, S; Zhou, K, 2018) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat." | 1.37 | Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. ( Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H, 2011) |
| "Propafenone was stereoselective, with R-propafenone suppressing waves more potently than S-propafenone (IC(50): R-propafenone 2 ± 0." | 1.37 | Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. ( Galimberti, ES; Knollmann, BC, 2011) |
| "Electrocardiography (ECG) showed ventricular tachycardia." | 1.35 | A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009) |
| "Spontaneous monomorphic and polymorphic ventricular tachycardias (VT) were observed during monitoring." | 1.33 | Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report. ( Dinckal, MH; Karaca, M, 2006) |
| "Propafenone is an antiarrhythmic drug used in the treatment of life-threatening ventricular tachyarrhythmias." | 1.30 | Propafenone-induced drug fever in the absence of agranulocytosis. ( Gerling, BR; Greenberg, ML; Holzberger, PT; O'Rourke, DJ; Palac, RT, 1997) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 1.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| "Propafenone is an effective drug for the acute conversion of spontaneous monomorphic sustained ventricular tachycardia, especially in patients without organic heart disease." | 1.29 | [The efficacy and safety of intravenous propafenone in the acute treatment of spontaneous sustained ventricular tachycardia]. ( Madrid, AH; Marín-Huerta, E; Mestre, JL; Moro, C; Novo, L, 1994) |
| "Propafenone is a class Ic anti-arrhythmic agent with mild beta-blocking properties which has recently become available in South Africa." | 1.29 | Normal left ventricular function does not protect against propafenone-induced incessant ventricular tachycardia. ( Lawrenson, JB; Millar, RN; Milne, DA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (58.14) | 18.2507 |
| 2000's | 7 (16.28) | 29.6817 |
| 2010's | 9 (20.93) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Cay, S | 1 |
| Kara, M | 1 |
| Ozcan, F | 1 |
| Ozeke, O | 1 |
| Aksu, T | 1 |
| Aras, D | 1 |
| Topaloglu, S | 1 |
| Basza, M | 1 |
| Maciejewski, C | 1 |
| Bojanowicz, W | 1 |
| Balsam, P | 1 |
| Grabowski, M | 1 |
| Mitkowski, P | 1 |
| Kempa, M | 1 |
| Kowalski, O | 1 |
| Kalarus, Z | 1 |
| Jaguszewski, M | 1 |
| Lubiński, A | 1 |
| Daniłowicz-Szymanowicz, L | 1 |
| Szumowski, Ł | 1 |
| Sterliński, M | 1 |
| Kołtowski, Ł | 1 |
| Bergonti, M | 1 |
| Assanelli, E | 1 |
| Agostoni, P | 1 |
| Rosa, M | 1 |
| Pappacoda, S | 1 |
| DʼAnna, C | 1 |
| Di Mita, O | 1 |
| Ponticiello, E | 1 |
| Marzuillo, P | 1 |
| Tipo, V | 1 |
| Duan, H | 1 |
| Lu, Y | 1 |
| Yan, S | 1 |
| Qiao, L | 1 |
| Hua, Y | 1 |
| Li, Y | 1 |
| Zhou, K | 1 |
| Wang, C | 1 |
| Lin, CY | 1 |
| Lin, YJ | 1 |
| Lo, LW | 1 |
| Chen, YY | 1 |
| Chong, E | 1 |
| Chang, SL | 1 |
| Chung, FP | 1 |
| Chao, TF | 1 |
| Hu, YF | 1 |
| Tuan, TC | 1 |
| Liao, JN | 1 |
| Chang, Y | 1 |
| Chien, KL | 1 |
| Chiou, CW | 1 |
| Chen, SA | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Ge, H | 1 |
| Gilewski, W | 1 |
| Bednarska, D | 1 |
| Sinkiewicz, W | 1 |
| Eroğlu, S | 1 |
| Ozin, B | 1 |
| Ozbiçer, S | 1 |
| Müderrisoğlu, H | 1 |
| Pino, R | 1 |
| Sciortino, G | 1 |
| Polizzi, G | 1 |
| Hwang, HS | 1 |
| Hasdemir, C | 2 |
| Laver, D | 1 |
| Mehra, D | 1 |
| Turhan, K | 1 |
| Faggioni, M | 1 |
| Yin, H | 1 |
| Knollmann, BC | 2 |
| Galimberti, ES | 1 |
| Musayev, O | 1 |
| Kehribar, DY | 1 |
| Kartal, Y | 1 |
| Can, LH | 1 |
| Büyükavci, M | 1 |
| Olgun, H | 1 |
| Kertmen, B | 1 |
| Tan, H | 1 |
| Ceviz, N | 1 |
| Karaca, M | 1 |
| Dinckal, MH | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Heusch, A | 1 |
| Kramer, HH | 1 |
| Krogmann, ON | 1 |
| Rammos, S | 1 |
| Bourgeous, M | 1 |
| Siebels, J | 4 |
| Cappato, R | 2 |
| Rüppel, R | 2 |
| Schneider, MA | 2 |
| Kuck, KH | 4 |
| Kantoch, MJ | 1 |
| Green, MS | 1 |
| Tang, AS | 1 |
| Mestre, JL | 1 |
| Moro, C | 1 |
| Madrid, AH | 1 |
| Novo, L | 1 |
| Marín-Huerta, E | 1 |
| Stark, G | 1 |
| Dhein, S | 1 |
| Bachernegg, M | 1 |
| Ziskoven, U | 1 |
| Zhao, Y | 1 |
| Klaus, W | 1 |
| Kickenweiz, E | 1 |
| Decrinis, M | 1 |
| Tritthart, HA | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Beaufort-Krol, GC | 1 |
| Bink-Boelkens, MT | 1 |
| Libersa, C | 1 |
| Caron, J | 1 |
| Broly, F | 1 |
| Lacroix, D | 1 |
| Lhermitte, M | 1 |
| Millar, RN | 1 |
| Lawrenson, JB | 1 |
| Milne, DA | 1 |
| Goedel-Meinen, L | 1 |
| van Hemel, NM | 1 |
| Kingma, JH | 1 |
| Defauw, JJ | 1 |
| Hoogteijling-van Dusseldorp, E | 1 |
| Kelder, JC | 1 |
| Beukema, WP | 1 |
| Vermeulen, FE | 1 |
| Stevens, SK | 1 |
| Haffajee, CI | 1 |
| Naccarelli, GV | 1 |
| Schwartz, KM | 1 |
| Luceri, RM | 1 |
| Packer, DL | 1 |
| Rubin, AM | 1 |
| Kowey, PR | 1 |
| Gillis, AM | 1 |
| Wyse, DG | 1 |
| Mitchell, LB | 1 |
| Duff, HJ | 1 |
| Botto, GL | 1 |
| Bonini, W | 1 |
| Broffoni, T | 1 |
| Molteni, S | 1 |
| Lombardi, R | 1 |
| Alfieri, G | 1 |
| Barone, P | 1 |
| Bernasconi, G | 1 |
| Ferrari, G | 1 |
| Oliveira, M | 1 |
| da Silva, N | 1 |
| Antunes, E | 1 |
| Pinto, E | 1 |
| Cotrim, C | 1 |
| Pitta, L | 1 |
| Cacela, D | 1 |
| Gracias, R | 1 |
| Antunes, AM | 1 |
| O'Rourke, DJ | 1 |
| Palac, RT | 1 |
| Holzberger, PT | 1 |
| Gerling, BR | 1 |
| Greenberg, ML | 1 |
| Gao, E | 1 |
| Yang, C | 1 |
| Li, H | 1 |
| Duan, Y | 1 |
| Zhou, Y | 1 |
| Mastropasqua, F | 1 |
| Totaro, P | 1 |
| Massari, F | 1 |
| Pitzalis, MV | 1 |
| Rizzon, P | 1 |
| Pinter, A | 1 |
| Dorian, P | 1 |
| Bauer, A | 1 |
| Schnabel, PA | 1 |
| Schreiner, KD | 1 |
| Becker, R | 1 |
| Voss, F | 1 |
| Kraft, P | 1 |
| Senges, J | 1 |
| Licka, M | 1 |
| Kübler, W | 1 |
| Schoels, W | 1 |
| Takanaka, C | 1 |
| Nonokawa, M | 1 |
| Machii, T | 1 |
| Lee, S | 1 |
| Kato, H | 1 |
| Haruna, M | 1 |
| Yabe, S | 1 |
| Lombardi, F | 2 |
| Torzillo, D | 2 |
| Sandrone, G | 2 |
| Dalla Vecchia, L | 2 |
| Cappiello, E | 2 |
| Finocchiaro, ML | 1 |
| Bernasconi, R | 1 |
| Herms, J | 1 |
| Schneider, M | 1 |
4 reviews available for propafenone and Atrioventricular Nodal Re-Entrant Tachycardia
| Article | Year |
|---|---|
Flecainide in clinical practice.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Female; Flecainide; Humans; Pregnancy; Propafeno | 2023 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
[Guided anti-arrhythmia therapy by programmed ventricular stimulation. A case of arrhythmogenic dysplasia of the right ventricle].
Topics: Adult; Anti-Arrhythmia Agents; Biopsy; Cardiac Pacing, Artificial; Cardiomyopathies; Endocardium; Fe | 1997 |
Intravenous antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Procainamid | 2001 |
12 trials available for propafenone and Atrioventricular Nodal Re-Entrant Tachycardia
| Article | Year |
|---|---|
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Randomized cross-over evaluation of two adaptive pacing algorithms for the termination of ventricular tachycardia.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Bundle-Branch Block; Cardiac Pacing, Artificial; Defibri | 1993 |
Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Hea | 1994 |
Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of postinfarction ventricular tachycardia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Sot | 1996 |
Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Defibrillators, Impl | 1996 |
Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?
Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Atr | 1996 |
Preliminary study of the effects of metoprolol and propafenone on ventricular arrhythmia with positive ventricular late potential.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Male; Metoprolol; Middle Aged; P | 1997 |
[Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Do | 1998 |
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
[Prospective long-term ECG study of 100 patients surviving sudden cardiac death].
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardiography, A | 1992 |
27 other studies available for propafenone and Atrioventricular Nodal Re-Entrant Tachycardia
| Article | Year |
|---|---|
Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Car | 2022 |
The Wrong Drug That Led to the Right Diagnosis.
Topics: Action Potentials; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; D | 2019 |
Ventricular Tachycardia Induced by Propafenone Intoxication in a Pediatric Patient.
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Child, Preschool; Electrocardiography; Humans; | 2019 |
A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Death, Sudden, Cardiac; Delayed Diagnosis; Electrocardiog | 2018 |
Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Female; He | 2015 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
[Life-threatening ventricular arrhythmia during simultaneous administration of propafenone and sotatol].
Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Humans; Male; Middle Aged; P | 2009 |
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable | 2009 |
Brugada-like phenomenon, induced by intravenous propafenone, in a patient with idiopathic fascicular ventricular tachycardia.
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Heart Co | 2013 |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defi | 2011 |
Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Calcium Signaling; Calsequestrin; Cell Membrane Permeabili | 2011 |
Chronic cough and tachycardia-induced cardiomyopathy in a patient with idiopathic frequent, monomorphic premature ventricular contractions.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chronic Disease; Cough; Female; Humans; Propafenone; | 2013 |
Ventricular tachycardia as a presenting symptom in a child with thrombotic thrombocytopenic purpura.
Topics: Adolescent; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Female; Humans; Me | 2004 |
Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report.
Topics: Adult; Ajmaline; Anti-Arrhythmia Agents; Brugada Syndrome; Bundle-Branch Block; Defibrillators, Impl | 2006 |
Clinical experience with propafenone for cardiac arrhythmias in the young.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Cardiac Complexes, Premature | 1994 |
[The efficacy and safety of intravenous propafenone in the acute treatment of spontaneous sustained ventricular tachycardia].
Topics: Acute Disease; Aged; Chi-Square Distribution; Drug Evaluation; Electrocardiography; Female; Humans; | 1994 |
Frequency-dependent effects of propafenone decrease with duration of ventricular tachycardia in isolated guinea pig hearts.
Topics: Action Potentials; Animals; Electrocardiography; Female; Guinea Pigs; Heart Conduction System; In Vi | 1994 |
Oral propafenone as treatment for incessant supraventricular and ventricular tachycardia in children.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; | 1993 |
Interaction of propafenone and mexiletine.
Topics: Drug Interactions; Drug Therapy, Combination; Humans; Mexiletine; Propafenone; Tachycardia, Ventricu | 1993 |
Normal left ventricular function does not protect against propafenone-induced incessant ventricular tachycardia.
Topics: Adult; Electrocardiography; Humans; Male; Propafenone; Tachycardia, Ventricular; Ventricular Functio | 1993 |
[Syncope in Lown IVb ventricular arrhythmias and mitral valve prolapse].
Topics: Adult; Electrocardiography, Ambulatory; Humans; Male; Mitral Valve Prolapse; Propafenone; Syncope; T | 1993 |
Propafenone pharmacokinetics and pharmacodynamics in patients with sustained ventricular tachycardia.
Topics: Aged; Anti-Arrhythmia Agents; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardium; Propafe | 1996 |
Propafenone-induced drug fever in the absence of agranulocytosis.
Topics: Agranulocytosis; Anti-Arrhythmia Agents; Diagnosis, Differential; Fever; Humans; Leukocyte Count; Ma | 1997 |
Effects of propafenone on anisotropic conduction properties within the three-dimensional structure of the canine ventricular wall.
Topics: Animals; Anisotropy; Anti-Arrhythmia Agents; Dogs; Heart; Heart Ventricles; Membrane Potentials; Myo | 2001 |
Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Therapy, Combination; Electrocardiography; | 1992 |
Autonomic effects of antiarrhythmic drugs and their importance.
Topics: Adult; Autonomic Nervous System; Cardiac Complexes, Premature; Electrocardiography; Female; Flecaini | 1992 |
Beta-blocking effect of propafenone based on spectral analysis of heart rate variability.
Topics: Adrenergic beta-Antagonists; Electrocardiography; Heart Rate; Humans; Posture; Propafenone; Receptor | 1992 |